Morgans Financial Limited Interviews CEO Steven Lydeamore
Steve spoke with Scott about the Company's plans in human gastrointestinal health; developing its unique natural dietary supplement to help Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) patients.
Following on from the Company's successful in vitro proof of concept studies, Anatara will now move its Gastrointestinal ReProgramming dietary supplement into the final stage of pre-clinical development for IBD with mouse studies expected to be completed by end of July 2019. In parallel, the Company will commence planning for a human observational study for IBS, with patient recruitment anticipated to start in the second half of 2019.
To view Scott's interview with Steve, please visit:
To view latest Corporate Fact Sheet, please visit:
About Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
Anatara Lifesciences Ltd